Liquidia Corp Ordinary Shares LQDA
News
LIQUIDIA CORPORATION LQDA INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57.2% Share Drop
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026


